<DOC>
	<DOCNO>NCT01872442</DOCNO>
	<brief_summary>Interferon alpha therapy use Chronic Myeloid Leukemia Chronic phase prior advent tyrosine kinase inhibitor . Synergistic effect combination Peg-IFNα2a Imatinib demonstrate clinical SPIRIT trial . In study , investigator address question efficacy safety dasatinib combination low dose Peg-IFNα-2b frontline therapy patient newly diagnose Chronic Myeloid Leukemia Chronic phase .</brief_summary>
	<brief_title>Combination Dasatinib Peg-Interferon Alpha 2b First Line Chronic Myeloid Leukemia Chronic Phase</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>1 . Signed Written Informed Consent . 2 . Target Population ) 18 65 year b ) Newly diagnose ( ≤ 3 month ) Philadelphia chromosome positive chronic CPCML c ) Major BCRABL transcript ) Not previously treat CML except hydroxyurea anagrelide e ) ECOG Performance Status≤ 2 f ) Adequate Organ Function . ) Total bilirubin &lt; 2.0 time institutional Upper Limit Normal ii ) Hepatic enzyme ( AST , ALT ) ≤ 2.5 ULN iii ) Serum Na , K+ , Mg2+ Ca2+ &gt; Lower Limit Normal ( LLN ) supplement iv ) Serum Creatinine &lt; 1.5 ULN g ) Women childbearing potential ( WOCBP ) must use adequate method contraception . 3 . Free subject , without guardianship subordination , 4 . Health insurance coverage . 1 . Patients BCRABL MBCRABL , Philadelphia negative CML . 2 . Patients previously treat Tyrosine Kinase Inhibitors ( TKIs ) . 3 . Medical history concurrent disease : 1 . Hypersensitivity excipients dasatinib 2 . Prior treatment Interferonα , contraindication interferonα , hypersensitivity excipients PegIFNα2b , 3 . Concomitant immunosuppressive treatment corticosteroid , 4 . Preexisting thyroid disease unless controlled conventional treatment , Autoimmune thyroiditis , 5 . Autoimmune disorder , Chronic liver disease , 6 . Prior ongoing severe psychiatric disease , 7 . Epilepsy compromised central nervous system ( CNS ) function , 8 . HIV positivity , chronic hepatitis B C , 9 . Uncontrolled significant cardio vascular pulmonary disease , ) Uncontrolled angina , myocardial infarction congestive heart failure within 6 month , ii ) Echocardiography LVF &lt; 45 % LLN , peak velocity tricuspid regurgitant flow &gt; 2,8 m/s iii ) Pulmonary arterial hypertension ( PAH ) , iv ) Any history clinically significant ventricular supraventricular arrhythmia , v ) Diagnosed congenital long QT syndrome , vi ) Prolonged QTc interval &gt; 450 msec ( Fredericia ) 3 preentry electrocardiogram , vii ) Subjects hypokalemia hypomagnesemia correct , j ) Other malignant disease last 5 year prior inclusion except basal cell carcinoma skin carcinoma situ cervix , k ) History significant bleeding disorder unrelated CML , include : ) Diagnosed congenital bleeding disorder ( e.g . von Willebrand 's disease ) , ii ) Ongoing recent ( ≤ 3 month ) significant gastrointestinal bleeding . l ) Another severe life threaten medical disease . 4 . Women pregnant breastfeeding , WOCBP unwilling unable use acceptable method avoid pregnancy entire study period least 4 week last dose study drug . 5 . Prohibited treatment and/or therapy : 1. strong inhibitor CYP3A4 , 2. category I drug generally accept risk cause `` Torsades de Pointes '' , Patients must discontinue drug minimum 7 day prior start dasatinib . 6 . History /any condition poor compliance treatment . 7 . Inability freely provide consent judiciary administrative condition . 8 . Ongoing participation another study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>